Protein secondary structure in spider silk nanofibrils

por Wang, Qijue, McArdle, Patrick, Wang, Stephanie L., Wilmington, Ryan L., Xing, Zhen, Greenwood, Alexander, Cotten, Myriam L., Qazilbash, M. Mumtaz, Schniepp, Hannes C.
Publicado 2022

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

por Shah, J J, Feng, L, Thomas, S K, Berkova, Z, Weber, D M, Wang, M, Qazilbash, M H, Champlin, R E, Mendoza, T R, Cleeland, C, Orlowski, R Z
Publicado 2016

The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma

por Wu, W, Merriman, K, Nabaah, A, Seval, N, Seval, D, Lin, H, Wang, M, Qazilbash, M H, Baladandayuthapani, V, Berry, D, Orlowski, R Z, Lee, M-H, Yeung, S-C J
Publicado 2014

P1376: LENALIDOMIDE–BASED MAINTENANCE AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT FOR PATIENTS WITH HIGH RISK MULTIPLE MYELOMA

por Pasvolsky, O., Milton, D., Rauf, M., Tanner, M., Bashir, Q., Srour, S., Saini, N., Ramdial, J., Nieto, Y., Lee, H., Patel, K., Kebriaei, P., Thomas, S., Weber, D., Orlowski, R., Shpall, E., Champlin, R., Qazilbash, M.
Publicado 2022